HIMS Stock Today: $1.15B Eucalyptus Deal Accelerates Global Push – February 20

HIMS stock is in focus on 20 February after Hims & Hers (HIMS) agreed to acquire Australia’s Eucalyptus in a deal valued at up to US$1.15 billion, or about A$1.6 billion. The Hims & Hers deal signals faster telehealth expansion across Australia and other new markets. For local investors, the Eucalyptus acquisition could boost brand reach in categories like skincare, hair loss, sexual health, and weight care. We break down what this means for growth, valuation, and risks that could sway HIMS stock near term.

Deal snapshot and AU relevance

Hims & Hers will buy Eucalyptus for up to US$1.15 billion, which Australian media pegs at roughly A$1.6 billion, including potential earn-outs tied to performance. The company frames it as a springboard for global growth and a deeper footprint in regulated markets. For details on pricing and rationale, see coverage from the Wall Street Journal source.

Eucalyptus runs digital clinics across key wellness categories with Australian clinicians and pharmacy partners. The tie-up could widen access to prescription and over-the-counter pathways, while keeping compliance with local standards. The Australian Financial Review reports the sale at A$1.6 billion and notes the strategic fit with Hims & Hers’ direct-to-consumer model source. The move may improve delivery speed and choice for Australian users.

Growth drivers and cross-sell potential

The combined network can cross-sell into hair loss, sexual health, dermatology, mental health, and weight care. Eucalyptus brings local brand trust and clinician supply, while Hims & Hers adds product breadth and marketing scale. If executed well, this can lift average order value and subscription stickiness. That is a medium-term lever that could support HIMS stock as new cohorts convert.

Eucalyptus gives immediate Australian scale, plus a base to test offers across APAC. Faster product launches and shared telehealth tooling can improve conversion and refill rates. We expect go-to-market wins first in categories with clear demand signals and simple pathways. Investors will watch if customer acquisition costs trend lower, which would be positive for unit economics and HIMS stock sentiment.

HIMS stock reaction and valuation setup

Recent trade shows HIMS at US$15.82, down 0.13% on the day, with a US$15.46 low and US$16.55 high. Year high is US$72.98 and year low is US$15.46. RSI sits at 16.62, which is oversold, while ADX at 53.20 signals a strong downtrend. Volume of 32.35 million exceeds the 20.63 million average. Technically, HIMS stock is stretched, so news-driven bounces are possible.

TTM P/E is 26.9 and price-to-sales is 1.58, with gross margin near 75.0% and ROE at 24.7%. Debt-to-equity is 1.92 and net debt to EBITDA is 4.89. Analysts skew mixed: 4 Buy, 12 Hold, 10 Sell. Earnings are slated for 23 February 2026 UTC. Our model grade shows B+ with a BUY tilt, while another composite rating is C+ with a Sell lean.

Risks, integration, and what to watch

Integration can face clinician retention, data privacy, and tech stack alignment issues. Regulatory approvals and ongoing compliance matter given Australia’s standards for prescribing and telehealth. Funding the deal must balance growth with leverage, since current ratio is 1.88 and free cash flow yield is about 3.8%. Any disruption to service levels could weigh on churn and HIMS stock.

Look for guidance on deal close timing, integration costs, and synergy phasing. Track Australian cohort growth, repeat order rates, and cross-sell penetration by category. Management commentary on acquisition payback, CAC trends, and marketing efficiency will be key. The 23 February earnings call is a near-term catalyst to set expectations for the Eucalyptus acquisition and broader telehealth expansion.

Final Thoughts

For Australian investors, the Eucalyptus acquisition puts Hims & Hers on the front foot in local telehealth, with an estimated A$1.6 billion transaction backing a clear scale play. The prize is better cross-sell, improved unit economics, and faster product cycles. The risks are real, including integration, regulation, and leverage. Near term, technicals show HIMS stock is oversold, which can sharpen reactions to updates. We suggest watching the 23 February earnings call for integration timelines, synergy targets, CAC trends, and category growth plans. Clear milestones, steady service quality, and disciplined spend would support a rerating of HIMS stock as the Hims & Hers deal progresses.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes.  Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.